Translocation Transfer

Olga Genilloud


Fundación MEDINA
Avenida Conocimiento 34


Phone: +34 699 451 966

Current Position:

Scientific Director; Head Microbiology Department

Key words:

natural products, drug discovery, antibacterials, HTS platform, natural products chemistry and biosynthesis, molecular microbiology, preclinical safety metabolomics


MEDINA has a natural products drug discovery platform which integrates full high throughput screening capacities with a multidisciplinary research team involving natural product chemists (Fernando Reyes, Chemistry Head), biologists (Francisca Vicente, Screening Head) and microbiologists (Olga Genilloud, Microbiology Head). Our principal focus in infectious diseases is to discover novel antibacterial molecules and to validate their activity profile as starting points for lead development. Our discovery strategies are both target based and phenotypic, and we offer broad panels of pathogens, whole cell-based assays for targeted mode of action screens and in vitro mass spectrometry assay technologies for the discovery of new natural products antibiotics. Key supporting elements we offer within projects are new structure elucidation, metabolomic and molecular studies of the mechanism of biosynthesis, microbiological activity profiling, drug metabolism and preclinical toxicity and safety profiling of the compounds. MEDINA is member of ENABLE (IMI-New Drugs for bad Bugs), a high capacity screening center of EU-OPENSCREEN-ERIC, member of the new VRI-NETWORK-IRAADD, and associated partner of the BEAM Alliance. Currently we actively develop discovery programs to identify novel antibiotics against Gram negative pathogens from our natural products libraries.

Role in the network:

Validation of new tools and targets to support the development of new strategies in antibiotic discovery integrating whole cell and target based assays.


  • Structure elucidation and biosynthetic gene cluster analysis of caniferolides A-D, new bioactive 36-membered macrolides from the marine-derived Streptomyces caniferus CA-271066. Pérez-Victoria I, Oves-Costales D, Lacret R, Martín J, Sánchez-Hidalgo M, Díaz C, Cautain B, Vicente F, Genilloud O, Reyes F. Org Biomol Chem. 2019 17(11):2954-297.
  • Mining Actinomycetes for Novel Antibiotics in the Omics Era: Are We Ready to Exploit This New Paradigm?Genilloud O. (2018). Antibiotics (Basel) 7(4).pii: E85. doi: 10.3390/antibiotics7040085.
  • Phocoenamicins B and C, New Antibacterial Spirotetronates Isolated from a Marine Micromonospora sp.Pérez-Bonilla M, Oves-Costales D, de la Cruz M, KokkiniM, Martín J, Vicente F, Genilloud O, Reyes F.(2018), Mar Drugs16(3) doi: 10.3390/md16030095 Actinomycetes: still a source of novel antibiotics.Genilloud O. (2017). Nat Prod Rep. 34:1203-1232.